Abstract
Both luteal-phase lupron downregulation (luteal lupron) and ganirelix have been shown to be efficacious in preventing a luteinizing hormone (LH) surge in ART cycles. Based on the work of the North American Ganirelix Group, ganirelix has been shown to be safe and effective with a reduction in the number of injections, ampules of gonadotropins, and days of stimulation with a modest decrease in pregnancy rates. The purpose of this analysis was to evaluate the relative cost differences per cycle and per pregnancy achieved by both methods of LH surge suppression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have